Curaleaf Q2 Revenue Reaches $340M, Swings to Profit as Cannabis Rescheduling Unlocks $65M Tax Benefit
CURLF sits 86% above its 52-week low of $4.485.
Summary
Curaleaf reported Q2 2026 revenue of $340 million, up 10% year-over-year, and swung to a net profit of $12.5 million. A $65.1 million tax benefit from the rescheduling of medical cannabis to Schedule III drove the earnings beat and reduced the uncertain tax position liability to $468.5 million.
Key Events · Earnings and Guidance · CURLF
-
Revenue Grows 10% to $340M
Q2 2026 revenue reached $340 million, driven by a 26% surge in international sales to $51 million. Domestic wholesale revenue grew 20%.
-
Swings to Net Profit on Tax Benefit
Net income from continuing operations was $12.5 million, compared to a $48.1 million loss a year ago. The turnaround was fueled by a $38.8 million income tax benefit, including a $65.1 million release of valuation allowances after medical cannabis was rescheduled to Schedule III.
-
Uncertain Tax Position Liability Drops
The uncertain tax position liability fell to $468.5 million from $531.5 million at year-end 2025, reflecting the rescheduling impact and a net release of $94.5 million in Q1 2026.
-
Balance Sheet Strengthened
Cash and equivalents stood at $94.6 million. The company refinanced $500 million of senior secured notes due 2026 with new notes due 2029, and settled the Four20 Pharma put option for $101.2 million, consolidating ownership.
Analysis · CURLF · Life Sciences
A solid quarter saw revenue climb 10% to $340 million and a swing to net income from a year-ago loss. The standout development is the $65.1 million tax benefit stemming from the April 2026 rescheduling of medical cannabis to Schedule III, which enabled the release of valuation allowances and a sharp reduction in the uncertain tax position liability. This regulatory tailwind represents a structural improvement to earnings power, not a one-time item. The balance sheet also strengthened: a $500 million notes refinancing pushed maturities to 2029, and the Four20 Pharma buyout was settled. Governance moves—a reverse stock split and an option exchange program—signal steps toward a potential U.S. exchange uplisting. The Hello Farms litigation remains a risk, though the company's accrual is well below the $37.2 million judgment.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 37.1% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.72%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $8.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $4.49 to $15.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.